Tuesday, 17 November 2026European Markets

BIOSENIC Stock Drops By 22% In The Last 10 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of BIOSENIC (BEL 20: BIOS.BR) slid by a staggering 22.41% in 10 sessions from €0.12 to €0.09 at 14:13 EST on Thursday, following the last session's upward trend. BEL 20 is sliding 0.61% to €3,537.32, after five consecutive sessions in a row of losses.

About BIOSENIC

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.01.

More news about BIOSENIC (BIOS.BR).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 22 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›